Chidamide R-CHOP Combination Therapy B-cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diffuse large B-cell lymphoma, particularly in high-risk and elderly patients, show limited efficacy with the R-CHOP regimen, with only about 70% complete response rate and poor long-term survival, indicating a need for improved therapeutic options.
Innovation Solution
Combining Chidamide, a subtype selective histone deacetylase inhibitor, with the R-CHOP regimen, which includes rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone, to enhance treatment efficacy through synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If R-CHOP regimen is used as standard first-line treatment for diffuse large B-cell lymphoma, then long-term survival is achieved in many patients, but complete response rate is limited to about 70% and long-term survival remains poor for high-risk elderly patients
Solution Approach 1:
The patent combines Chidamide (a HDAC inhibitor) with the existing R-CHOP regimen to create a new combination therapy. This merging of a targeted epigenetic modifier with conventional chemotherapy aims to achieve synergistic effects, improving complete response rates while building upon the established backbone of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Solution Approach 2:
The treatment approach uses a composite therapeutic strategy by integrating Chidamide (an oral HDAC inhibitor with specific subtype selectivity) with the R-CHOP regimen. This composite approach leverages the epigenetic modulation properties of Chidamide alongside the multi-mechanism chemotherapy of R-CHOP to address treatment resistance and improve outcomes in high-risk patients.
2Reliability
If conventional immunochemotherapy is used, then treatment is standardized and manageable, but 1/3 of patients have no response or relapse indicating insufficient efficacy
Solution Approach 1:
The patent introduces Chidamide, an oral HDAC inhibitor with specific pharmacokinetic and pharmacodynamic properties, to change the therapeutic parameters of the treatment regimen. This addition modifies the mechanism of action profile by targeting epigenetic modifications, thereby improving efficacy in patients who do not respond adequately to conventional R-CHOP therapy.
3Reliability
If R-CHOP regimen is used for high-risk elderly patients, then treatment is feasible, but complete response rate is only about 70% with poor long-term survival
Solution Approach 1:
The patent merges Chidamide with R-CHOP to create an enhanced regimen for high-risk elderly patients. This combination maintains the feasibility of treatment while aiming to improve complete response rates beyond the 70% achieved with R-CHOP alone, addressing the unmet need in this vulnerable patient population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of Chidamide with R-CHOP significantly improves treatment outcomes for newly-treated, high-risk, and elderly diffuse large B-cell lymphoma patients, achieving a complete response rate of 87% and overall response rate of 100% in clinical trials, surpassing the efficacy of the R-CHOP regimen alone.
Implementation Method 1
Chidamide mainly targets the subtypes 1, 2 and 3 of class I and the subtype 10 of class IIb of HDAC, and has a regulatory effect on abnormal epigenetic functions of tumors. It induces chromatin remodeling by inhibiting related HDAC subtypes to increase the acetylation level of chromatin histone
Implementation Method 2
thereby leading to alterations in gene expression of multiple signaling pathways (i.e., epigenetic alterations), thereby inhibiting tumor cell cycle and inducing tumor cell apoptosis
Implementation Method 3
having overall regulatory activity on the body's cellular immunity, and inducing and enhancing the tumor killing effect mediated by natural killer cells (NK) and antigen-specific cytotoxic T cells (CTL)
Data Source
AI summary
The present application provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma.